Satellos Bioscience Inc. MSLE
Satellos Bioscience Inc. (Nasdaq: MSLE) is a rare genetic drug developer. Its lead program, Forazapadin (SAT-3247), oral AAK1 inhibitor, is in Phase 2 for Duchenne muscular dystrophy (DMD). Its next catalyst on record is Forazapadin (SAT-3247): Start of Phase 2 trial in adults with FSHD (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Forazapadin (SAT-3247) — Start of Phase 2 trial in adults with FSHD (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Forazapadin (SAT-3247) - BASECAMP (pediatric DMD, randomized placebo-controlled) | DMD | small molecule | Phase 2 |
| Forazapadin (SAT-3247) - TRAILHEAD (adult DMD, open-label long-term follow-up) | DMD | small molecule | Phase 2 |
| Forazapadin (SAT-3247) - FSHD adults | Facioscapulohumeral muscular dystrophy (FSHD) | small molecule | Pre-clinical |
| SAT-3153 (back-up AAK1 inhibitor) | DMD | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.